Publication | Open Access

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Hematological MalignancyOncologyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaHematologyMyeloid NeoplasiaMalignant Blood DisorderPharmacotherapyAntisense OligonucleotideAntisense TherapyPharmacologyRadiation OncologyHealth Sciences